Cystic Fibrosis

Fourth time lucky for CF drug’s PBS listing bid

After being knocked back three times for PBS listing, the cystic fibrosis treatment lumacaftor with ivacaftor (Orkambi) has received a positive recommendation from the Pharmaceutical Benefits Advisory Committee At its July meeting the PBAC made  a recommendation for a Section 100 (Highly Specialised Drugs Program) Authority Required listing for the drug as treatment of cystic ...

Already a member?

Login to keep reading.

© 2022 the limbic